Gene Therapy Shows Durable 5-Year Protection in Adults With Hemophilia B One infusion of etranacogene dezaparvovec-drlb for hemophilia B provides lasting bleed protection, stable FIX for 5 years, and a favorable safety profile.

Nearly all (94%) responders were able to discontinue continuous prophylactic #FIXTherapy, and exogenous FIX use dropped by 96%.

Read here: https://bit.ly/4a6LqS2

#RareDisease #Hemophilia #Hematology #Hemgenix® #HemophiliaB